ValiRx gives NHS Long Term Plan its seal of approval
(Sharecast News) - Clinical stage biotechnology company ValiRx endorsed the Government's new NHS Long Term Plan to improve the quality of patient care and health outcomes on Wednesday.
Read moreThu, 17th Jun 2010 08:14
(Sharecast News) - Clinical stage biotechnology company ValiRx endorsed the Government's new NHS Long Term Plan to improve the quality of patient care and health outcomes on Wednesday.
Read moreLONDON (Alliance News) - Biotechnology firm ValiRx PLC on Wednesday said it endorses the UK government's new NHS long-term plan."The government's recently announced ten-year a
Read more(Sharecast News) - Clinical stage biotechnology company ValiRx announced the acceptance for publication of the first article containing results from the VAL401 clinical trial by the European Journal of Drug Metabolism and Pharmacokinetics on Tuesday.
Read more(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Monday that independent analysis of VAL201 data showed a "statistically significant" dose dependant response in the reduction of PSA correlated to time on the Phase l/ll clinical trial, involving patients with hormone-sensitive and hormone-resistant prostate cancer.
Read moreLONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------NMC up The
Read moreLONDON (Alliance News) - ValiRx PLC on Monday said an independent analysis of VAL201 showed a positive effect on patients with hormone-sensitive and hormone-resistant prostate cancer.The up
Read more(Sharecast News) - Clinical stage biotechnology company ValiRx's leading anti-cancer therapeutic has entered the concluding stages of its Phase l/ll clinical trial at University College London Hospital.
Read moreLONDON (Alliance News) - Life science company ValiRx PLC on Tuesday reported a widened loss in the first half of 2018 due to expenses and a sizeable share option charge.The company's to
Read moreLONDON (Alliance News) - Clinical stage biotechnology company ValiRx PLC said Thursday its clinical study report on lung cancer drug VAL401 has been signed and approved by principal in ValiRx were
Read more(Sharecast News) - ValiRx told investors on Thursday that its clinical-stage therapeutics had continued to demonstrate "significant potential" for addressing unmet medical needs in oncology.
Read moreLONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - up 2.6%. The jet engine maker said it will cut
Read moreLONDON (Alliance News) - ValiRx PLC said Friday Nicholas Slater had almost doubled his stake in life science company, which focuses on cancer treatments, to 4.5% after a transaction on raised his
Read moreLONDON (Alliance News) - ValiRx PLC said Friday it has raised GBP950,000 through the issue of 47.5 million shares at 2.00 pence per share.The clinical stage biotechnology company's down
Read moreLONDON (Alliance News) - Biotechnology company ValiRx PLC said Wednesday its VAL201 compound has been granted a patent in the EU.This, it said, follows a US patent which was granted for a a
Read moreLONDON (Alliance News) - ValiRx PLC on Thursday said pre-clinical studies showed that its VAL101 compund has a potential to prevent cancer growth at cellular biochemical and genomic molecule is is
Read more